Marshall Wace
STRO icon

Marshall Wace’s Sutro Biopharma STRO Stock Holding History

Marshall Wace’s Portfolio STRO Stock Details STRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.82M Sell
175,246
-47,388
-21% -$1.48M ﹤0.01% 1291
2026
Q1 		$5.55M Buy
222,634
+137,019
+160% +$2.48M 0.01% 1253
2025
Q4 		$991K Buy
85,615
+73,771
+623% +$700K ﹤0.01% 1938
2025
Q3 		$103K Sell
11,844
-11,599
-49% -$98.7K ﹤0.01% 2654
2025
Q2 		$166K Buy
+23,443
New +$192K ﹤0.01% 2483
2024
Q4 		– Sell
-3,066
Closed -$106K – 2990
2024
Q3 		$106K Buy
+3,066
New +$120K ﹤0.01% 2368
2023
Q2 		– Sell
-21,791
Closed -$1.01M – 2949
2023
Q1 		$1.01M Sell
21,791
-34,201
-61% -$2.17M ﹤0.01% 1807
2022
Q4 		$4.52M Buy
55,992
+3,630
+7% +$252K 0.01% 1253
2022
Q3 		$2.91M Sell
52,362
-5,062
-9% -$300K 0.01% 1776
2022
Q2 		$2.99M Buy
+57,424
New +$3.21M 0.01% 1715
2021
Q3 		– Sell
-11,490
Closed -$2.14M – 3413
2021
Q2 		$2.14M Sell
11,490
-20,554
-64% -$4.02M 0.01% 1379
2021
Q1 		$7.29M Buy
32,044
+734
+2% +$174K 0.03% 624
2020
Q4 		$6.8M Buy
+31,310
New +$5.18M 0.04% 468

Other funds holding STRO

PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Marshall Wace's STRO Position: Q2 2026 in Review

Marshall Wace reduced its Sutro Biopharma (STRO) stake by 21% in Q2 2026, selling an estimated $1.48M and leaving 175,246 shares worth $5.82M. The position accounts for ﹤0.01% of the portfolio, ranked #1291.

Marshall Wace first reported a position in STRO in Q4 2020 and has held it in 13 quarters since. The position peaked at $7.29M in Q1 2021. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

  • Marshall Wace held 175,246 shares of Sutro Biopharma worth $5.82M as of Q2 2026.
  • Marshall Wace sold 47,388 Sutro Biopharma shares in Q2 2026, an estimated $1.48M.
  • Sutro Biopharma made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #1291 holding.
  • Marshall Wace first reported a position in Sutro Biopharma in Q4 2020 and has held it in 13 quarters since.
  • Marshall Wace's Sutro Biopharma position peaked at $7.29M in Q1 2021.
  • 100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.